There was no evidence for a significantly differential treatment effect of telmisartan in hypertensive and nonhypertensive patients for any endpoints , although the occurrence of the secondary three-fold endpoint was significantly lower in the telmisartan group ( @ % ) compared with placebo ( @ % , P < @ ) only in hypertensive patients .